Dermatofibrosarcoma protuberans is a slow-growing tumor of fibroblastic or histiocytic origin originating in the dermis and later developing as numerous nodules on a plaque. It has a slowly progressive course, is locally aggressive, and is prone to recurrence after surgery. Occasionally, there is widespread dissemination, but metastasis is rare. The clinical features are: raised firm plaques or nodules with a slightly concave, brownish or dark red skin surface and light blue-red surrounding skin. Surgical excision is the main treatment. The manner of surgical excision is very important. The surgical margins should be removed from the outer deep fascia of the tumor area to reduce the recurrence rate. Clinically, even with extensive excision, the recurrence rate of patients can be 11% to 50%. Surgical resection, with Mohs microsurgical resection, is recommended for critical lesions, and this procedure can significantly reduce the recurrence rate of the tumor. Rhabdomyosarcoma has a translocation between chromosome 17 and chromosome 22, leading to an upregulation of PDGF expression levels, and clinically, the application of griseofulvin can effectively inhibit tumor progression. A recent review of the literature summarized that of 74 patients treated with Gleevec for augmentation dermatofibrosarcoma, 48 patients (65%) showed no disease progression. These 74 patients were mainly those with large tumors that were difficult to remove surgically or where surgical removal could be severely disabling, or where recurrence and metastasis occurred. Therefore, clinical treatment with Gleevec can be tried first for this group of patients. Clinically, patients who develop Gleevec resistance can be treated with sunitinib, and some patients can still respond well after switching. The clinical approach and dosing of Gleevec varies. Some clinical studies have used 400 mg/day and some have used 800 mg/day. Some clinical studies use 400mg/day and then gradually increase the dosage to 800mg/day. Observe the toxic side effects during the use.